BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 22621641)

  • 1. BRAF inhibition in refractory hairy-cell leukemia.
    Dietrich S; Glimm H; Andrulis M; von Kalle C; Ho AD; Zenz T
    N Engl J Med; 2012 May; 366(21):2038-40. PubMed ID: 22621641
    [No Abstract]   [Full Text] [Related]  

  • 2. Hairy cell leukemia.
    Dearden C
    Best Pract Res Clin Haematol; 2015 Dec; 28(4):163-5. PubMed ID: 26614893
    [No Abstract]   [Full Text] [Related]  

  • 3. Continued response off treatment after BRAF inhibition in refractory hairy cell leukemia.
    Dietrich S; Hüllein J; Hundemer M; Lehners N; Jethwa A; Capper D; Acker T; Garvalov BK; Andrulis M; Blume C; Schulte C; Mandel T; Meissner J; Fröhling S; von Kalle C; Glimm H; Ho AD; Zenz T
    J Clin Oncol; 2013 Jul; 31(19):e300-3. PubMed ID: 23690412
    [No Abstract]   [Full Text] [Related]  

  • 4. BRAF inhibitor therapy in HCL.
    Dietrich S; Zenz T
    Best Pract Res Clin Haematol; 2015 Dec; 28(4):246-52. PubMed ID: 26614903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose vemurafenib induces complete remission in a case of hairy-cell leukemia with a V600E mutation.
    Peyrade F; Re D; Ginet C; Gastaud L; Allegra M; Ballotti R; Thyss A; Zenz T; Auberger P; Robert G
    Haematologica; 2013 Feb; 98(2):e20-2. PubMed ID: 23300174
    [No Abstract]   [Full Text] [Related]  

  • 6. Successful vemurafenib salvage treatment in a patient with primary refractory hairy cell leukemia and pulmonary aspergillosis.
    Maurer H; Haas P; Wengenmayer T; Lübbert M; Duyster J; Zeiser R
    Ann Hematol; 2014 Aug; 93(8):1439-40. PubMed ID: 24337488
    [No Abstract]   [Full Text] [Related]  

  • 7. Hairy cell leukemia: Past, present and future.
    Getta BM; Park JH; Tallman MS
    Best Pract Res Clin Haematol; 2015 Dec; 28(4):269-72. PubMed ID: 26614906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vemurafenib for relapsed or refractory hairy-cell leukaemia.
    Baker H
    Lancet Oncol; 2015 Oct; 16(13):e484. PubMed ID: 26387749
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy of vemurafenib in hairy-cell leukemia.
    Samuel J; Macip S; Dyer MJ
    N Engl J Med; 2014 Jan; 370(3):286-8. PubMed ID: 24428489
    [No Abstract]   [Full Text] [Related]  

  • 10. Hairy cell leukemia: update and current therapeutic approach.
    Salam L; Abdel-Wahab O
    Curr Opin Hematol; 2015 Jul; 22(4):355-61. PubMed ID: 26049757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New insights in the management of patients with hairy cell leukemia.
    Cornet E; Damaj G; Troussard X
    Curr Opin Oncol; 2015 Sep; 27(5):371-6. PubMed ID: 26154707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Historical overview of hairy cell leukemia.
    Andritsos LA; Grever MR
    Best Pract Res Clin Haematol; 2015 Dec; 28(4):166-74. PubMed ID: 26614894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRAF(V600E) mutation in a histiocytic sarcoma arising from hairy cell leukemia.
    Michonneau D; Kaltenbach S; Derrieux C; Trinquand A; Brouzes C; Gibault L; North MO; Delarue R; Varet B; Emile JF; Brousse N; Hermine O
    J Clin Oncol; 2014 Dec; 32(35):e117-21. PubMed ID: 24567436
    [No Abstract]   [Full Text] [Related]  

  • 14. Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia.
    Tiacci E; Park JH; De Carolis L; Chung SS; Broccoli A; Scott S; Zaja F; Devlin S; Pulsoni A; Chung YR; Cimminiello M; Kim E; Rossi D; Stone RM; Motta G; Saven A; Varettoni M; Altman JK; Anastasia A; Grever MR; Ambrosetti A; Rai KR; Fraticelli V; Lacouture ME; Carella AM; Levine RL; Leoni P; Rambaldi A; Falzetti F; Ascani S; Capponi M; Martelli MP; Park CY; Pileri SA; Rosen N; Foà R; Berger MF; Zinzani PL; Abdel-Wahab O; Falini B; Tallman MS
    N Engl J Med; 2015 Oct; 373(18):1733-47. PubMed ID: 26352686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid response of biallelic BRAF V600E mutated hairy cell leukaemia to low dose vemurafenib.
    Follows GA; Sims H; Bloxham DM; Zenz T; Hopper MA; Liu H; Bench A; Wright P; Van't Veer MB; Scott MA
    Br J Haematol; 2013 Apr; 161(1):150-3. PubMed ID: 23278307
    [No Abstract]   [Full Text] [Related]  

  • 16. Rapid and complete hematological response of refractory hairy cell leukemia to the BRAF inhibitor dabrafenib.
    Vergote V; Dierickx D; Janssens A; Verhoef G; Tousseyn T; Vandenberghe P; Wolter P; Delforge M
    Ann Hematol; 2014 Dec; 93(12):2087-9. PubMed ID: 24863690
    [No Abstract]   [Full Text] [Related]  

  • 17. Rapid response to vemurafenib in a heavily pretreated patient with hairy cell leukemia and a BRAF mutation.
    Munoz J; Schlette E; Kurzrock R
    J Clin Oncol; 2013 Jul; 31(20):e351-2. PubMed ID: 23733763
    [No Abstract]   [Full Text] [Related]  

  • 18. Long-term follow-up after purine analogue therapy in hairy cell leukaemia.
    Else M; Dearden CE; Catovsky D
    Best Pract Res Clin Haematol; 2015 Dec; 28(4):217-29. PubMed ID: 26614900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical features and diagnosis of hairy cell leukemia.
    Quest GR; Johnston JB
    Best Pract Res Clin Haematol; 2015 Dec; 28(4):180-92. PubMed ID: 26614896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Successful use of vemurafenib in a patient with resistant hairy cell leukemia].
    Urnova ES; Al'-Radi LS; Kuz'mina LA; Kariakina AA; Kovrigina AM; Dvirnyk VN; Iakutik IA; Sudarikov AB; Parovichnikova EN; Savchenko VG
    Ter Arkh; 2013; 85(7):76-8. PubMed ID: 24137951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.